[Quality of life of women with stress urinary incontinence with or without pollakiuria].
OBJECTIVE
Assess improvement in quality of life using a validated scale in women with urge incontinence or pollakiuria treated with oxybutynine.


METHODS
A prospective open multicentric trial was conducted in 1701 women aged 20 to 60 years (mean 47.6) with the last 2 months. Quality of life was assessed on the Ditrovie scale before and after a 3-month treatment with oxybutynin (7.5 to 15 mg/day).


RESULTS
Patient compliance was good (97%) and side effects rare (8%) (mainly dry mouth). There was a significant symptom improvement (p < or = 0.0001) between day 0 and day 90 after treatment: 48% of the women no longer had incontinence with a safety interval of more than 15 minutes compared with 0.2% prior to treatment; urge incontinence disappeared in 75% of the 81% affected women; 82% of the women had an intermictional interval longer than 2 hours after treatment compared with 33% prior to treatment. There was a significant improvement in the quality of life scores after treatment (p < 0.0001), as assessed by the overall score and subscores (daily life, emotional impact, self-image, sleep, well-being).


CONCLUSIONS
These findings demonstrate the efficacy of oxybutynine in improving urge incontinence and pollakiuria in women, both in terms of symptom relief and quality of life.
Amarenco
G
G
Service de Rééducation neurologique, Centre Hospitalier Robert Ballanger, Aulnay-sous-Bois. amarenco@infonie.fr
Marquis
P
P
McCarthy
C
C
Richard
F
F
D000328:Adult; D005260:Female; D006801:Humans; D008333:Mandelic Acids / Q000627:therapeutic use*; D008875:Middle Aged; D010276:Parasympatholytics / Q000627:therapeutic use*; D011446:Prospective Studies; D011788:Quality of Life; D016896:Treatment Outcome; D014550:Urinary Incontinence, Stress / Q000150:complications / Q000188:drug therapy*; D014555:Urination Disorders / Q000150:complications
D008333:Mandelic Acids; D010276:Parasympatholytics; C005419:oxybutynin
Qualité de vie des femmes souffrant d'impériosité mictionnelle avec ou sans fuites. Etude prospective après traitement par oxybutynine (1701 cas).